Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in IONS — Ionis Pharmaceuticals Inc

CIK 1423053 MIAMI, FL
Back to IONS Full portfolio

Position in IONS

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$70,774,877
-$98,096,176 QoQ
Shares Held
942,534
-55.8% QoQ
Ownership
0.570%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in IONS Over Time

Shares Held

Position Value (USD)

Derivatives in IONS

reported options exposure · as of Mar 31, 2026
CallValue
$8,657,877
CallShares
115,300
PutValue
$18,644,847
PutShares
248,300

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. IONS ranks #19 (1.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in IONS

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $70,774,877 942,534
2026-03-31 $18,644,847 248,300
2026-03-31 $8,657,877 115,300
2025-12-31 $168,871,053 2,134,636
2025-12-31 $5,458,590 69,000
2025-12-31 $8,654,634 109,400
2025-09-30 $7,183,116 109,800
2025-09-30 $157,143,091 2,402,065
2025-09-30 $4,978,462 76,100
2025-06-30 $3,559,851 90,100
2025-06-30 $2,259,972 57,200
2025-06-30 $59,066,698 1,494,981
2025-03-31 $2,353,260 78,000
2025-03-31 $1,746,843 57,900
2025-03-31 $104,993,469 3,480,062
2024-12-31 $2,101,096 60,100
2024-12-31 $75,720,422 2,165,916
2024-12-31 $1,307,504 37,400
2024-09-30 $1,586,376 39,600
2024-09-30 $2,279,414 56,900
2024-09-30 $16,070,108 401,151
2024-06-30 $6,920,232 145,200
2024-06-30 $2,630,832 55,200
2024-06-30 $29,884,392 627,033
2024-03-31 $3,382,600 78,030
2024-03-31 $1,647,300 38,000
2024-03-31 $5,973,630 137,800
2023-12-31 $2,347,376 46,400
2023-12-31 $12,775,391 252,528
2023-12-31 $1,001,682 19,800
2023-09-30 $1,555,848 34,300
2023-09-30 $24,309,239 535,918
2023-09-30 $362,880 8,000
2023-06-30 $2,092,530 51,000
2023-06-30 $29,614,551 721,778
2023-06-30 $718,025 17,500
2023-03-31 $260,902 7,300
2023-03-31 $5,415,432 151,523
2023-03-31 $1,383,138 38,700
2022-12-31 $876,264 23,200
2022-12-31 $1,333,281 35,300
2022-12-31 $14,939,772 395,546
2022-09-30 $18,498,400 418,232
2022-09-30 $2,224,769 50,300
2022-09-30 $928,830 21,000
2022-06-30 $17,774,893 480,143
2022-06-30 $732,996 19,800
2022-06-30 $1,902,828 51,400
2022-03-31 $46,097,168 1,244,524
2022-03-31 $977,856 26,400

Report a Problem

Category
Description
Email (optional, for follow-up)